TY - JOUR
T1 - Recommendations for Clinical Warfarin Genotyping Allele Selection
T2 - A Report of the Association for Molecular Pathology and the College of American Pathologists
AU - Pratt, Victoria M.
AU - Cavallari, Larisa H.
AU - Del Tredici, Andria L.
AU - Hachad, Houda
AU - Ji, Yuan
AU - Kalman, Lisa V.
AU - Ly, Reynold C.
AU - Moyer, Ann M.
AU - Scott, Stuart A.
AU - Whirl-Carrillo, Michelle
AU - Weck, Karen E.
N1 - Publisher Copyright:
© 2020 Association for Molecular Pathology and American Society for Investigative Pathology
PY - 2020/7
Y1 - 2020/7
N2 - The goal of the Association for Molecular Pathology (AMP) Clinical Practice Committee's AMP Pharmacogenomics (PGx) Working Group is to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations for a minimum panel of variant alleles (tier 1) and an extended panel of variant alleles (tier 2) that will aid clinical laboratories when designing assays for PGx testing. The AMP PGx Working Group considered functional impact of the variants, allele frequencies in multiethnic populations, the availability of reference materials, as well as other technical considerations for PGx testing when developing these recommendations. The ultimate goal is to promote standardization of PGx gene/allele testing across clinical laboratories. These recommendations are not to be interpreted as prescriptive but to provide a reference guide. Of note, a separate article with recommendations for CYP2C9 allele selection was previously developed by the PGx Working Group that can be applied broadly to CYP2C9-related medications. The warfarin allele recommendations in this report incorporate the previous CYP2C9 allele recommendations and additional genes and alleles that are specific to warfarin testing.
AB - The goal of the Association for Molecular Pathology (AMP) Clinical Practice Committee's AMP Pharmacogenomics (PGx) Working Group is to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document series provides recommendations for a minimum panel of variant alleles (tier 1) and an extended panel of variant alleles (tier 2) that will aid clinical laboratories when designing assays for PGx testing. The AMP PGx Working Group considered functional impact of the variants, allele frequencies in multiethnic populations, the availability of reference materials, as well as other technical considerations for PGx testing when developing these recommendations. The ultimate goal is to promote standardization of PGx gene/allele testing across clinical laboratories. These recommendations are not to be interpreted as prescriptive but to provide a reference guide. Of note, a separate article with recommendations for CYP2C9 allele selection was previously developed by the PGx Working Group that can be applied broadly to CYP2C9-related medications. The warfarin allele recommendations in this report incorporate the previous CYP2C9 allele recommendations and additional genes and alleles that are specific to warfarin testing.
UR - http://www.scopus.com/inward/record.url?scp=85086579266&partnerID=8YFLogxK
U2 - 10.1016/j.jmoldx.2020.04.204
DO - 10.1016/j.jmoldx.2020.04.204
M3 - Review article
C2 - 32380173
AN - SCOPUS:85086579266
SN - 1525-1578
VL - 22
SP - 847
EP - 859
JO - Journal of Molecular Diagnostics
JF - Journal of Molecular Diagnostics
IS - 7
ER -